PSORIASIS PSORIASIS. Anatomic sites FACTS ABOUT PROSIASIS PSORIASIS 11/16/2017 STIGMATA OF PSORIASIS

Similar documents
Psoriasis management. A/Prof Amanda Oakley Dermatologist, Waikato

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Psoriasis. What is Psoriasis? What causes psoriasis? Medical Topics Psoriasis

It is estimated that about 26,000 new cases of

Psoriasis. Andrei Metelitsa, MD, FRCPC, FAAD Clinical Associate Professor, Dermatology, U of C Co-Director, Institute for Skin Advancement

Psoriasis. Jessica Kaffenberger, M.D. Assistant Professor of Dermatology Division of Dermatology The Ohio State University Wexner Medical Center

An otherwise healthy 12-year-old

Psoriasis: Causes, Symptoms, And Treatment

Supplementary Tables. Psoriasis a

SELF-TEST QUESTIONNAIRE PSORIASIS. Plaque a raised lesion where the diameter is greater than the thickness. Number 2

Retrospective 10 years review of 100 patients with psoriasis in the Kingdom of Saudi Arabia (KSA)

COMMON SKIN CONDITIONS IN PRIMARY CARE. Ibrahim M. Zayneh, MD Dermatology Private Practice, Portsmouth, Ohio

Supplementary Online Content

This questionnaire was used both during the face-to-face interviews with the

What is Psoriasis? Common Areas Affected. Type Who Does it Affect Characteristics

Psoriasis in Jordan: a single center experience

KEY MESSAGES. Psoriasis patients are more prone to cardiovascular diseases, stroke, lymphoma and non-melanoma skin cancers, and increased mortality.

PDP SELF-TEST QUESTIONNAIRE PSORIASIS. Plaque a raised lesion where the diameter is greater than the thickness. Number 2

Psoriasis is a chronic, inflammatory, Prescribing in children

Predicting the Response to Phototherapy for Psoriasis Patients

Seronegative Arthritis. Dr Mary Gayed 25 th April 2018

Guttate psoriasis =ﻒدﺼﻠا ﻲﻄﻘﻨﻠا

Psoraisis = ﻒدﺼﻠا 1 / 84

Psoriasis. Causes of Psoriasis

Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults

Breakthrough Drugs in Dermatology. Mark Lebwohl, MD

The Natural History of Psoriasis and Treatment Goals

Psoriasis. Overview. Epidemiology. Epidemiology 08/08/2015. Dr Nigel Burrows Consultant Dermatologist Addenbrooke s Hospital

Psoriasis Case presentation 2 Ahmad is 50 years old male came to the on call dermatologist with a 3 day history of feeling generally unwell and

Difference Between Seborrheic Dermatitis and Psoriasis

The role of the practice nurse in managing psoriasis in primary care

chemotherapeutic agents in

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

Recognizing common Dermatologic conditions. Case presentations. CAPA 2015 Annual Conference. Tanya Nino, MD St. Joseph Heritage Medical Group

Psoriasiform Dermatitis in Children: Calling in the Troops

A Pilot Study. Name of investigational product:

Horizon Scanning Centre March Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798

Phototherapy and Photochemotherapy Treatment (Ultraviolet A [PUVA] and B [UBV])

TREATMENT OPTIONS FOR PSORIASIS. Sandra Hanlon Dermatology Senior Charge Nurse NHS Ayrshire and Arran 07/03/17

A Patient s Guide to. Treatments for Psoriatic Arthritis

Update on systemic therapies and emerging treatments How do I choose a systemic agent?

Rheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS

Elements of Successful PBS Applications. Barbara Radulski RN. Copyright

Psoriasis. School of Pharmacy, Faculty of Health Sciences, Sefako Makgatho Health Sciences University

The prevalence of psoriasis among human immunodeficiency

Clinical Trial Report Synopsis

Childhood psoriasis: Analytic retrospective study in Saudi patients

Volume 7, Edition 1 / Winter 07 93

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Topical Calcipotriol Algorithm

Some skin conditions

ustekinumab (Stelara )

1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.

PAPULOSQUAMOUS DISEASE AND VESICULOBULLOUS DISEASE

Contemporary Management of Moderate to Severe Plaque Psoriasis

INFLAMMATORY BOWEL DISEASE AND SKIN HEALTH KARA N. SHAH, MD, PHD KENWOOD DERMATOLOGY MARCH 4, 2018

Dermatology elective for yr. 5. Natta Rajatanavin, MD. Div. of dermatology Dep. Of Medicine, Ramathibodi Hospital Mahidol University 23 rd Feb 2015

Medication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014

Adalimumab M Clinical Study Report Final R&D/16/0603

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:

Background AN UPDATED LOOK AT TREATMENTS FOR PLAQUE PSORIASIS JULY 2018 PLAQUE PSORIASIS TARGETED IMMUNOMODULATORS AS A TREATMENT OPTION

STELARA (USTEKINUMAB)

STELARA (USTEKINUMAB)

What you need to know about PSORIASIS. Psoriasis

Psoriasis is an inflammatory condition of the skin that

Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris

STELARA (USTEKINUMAB)

Best Practices Pearls

A CLINICAL AND HISTOPATHOLOGICAL STUDY OF LICHEN PLANUS

Pharmacy Accreditation

PSORIASIS BEST PRACTICE IN MANAGEMENT

Current treatment options in the management of psoriasis

Insights from the Clalit Health Services database about Psoriasis Research using BIG DATA Arnon D. Cohen, MD, MPH, PHD

Targeted Immunomodulators for the Treatment of Moderate-to- Severe Plaque Psoriasis: Effectiveness and Value

Psoriasis Penis - A Two Case Report

Nail diseases This page outlines the terms used by dermatologists to describe diseases of the fingernails and toenails.

Research gaps in psoriasis: Opportunities for future studies

2017 Blue Cross and Blue Shield of Louisiana

Pediatric Use: Safety and effectiveness of Ustekinumab (STELARA ) in pediatric patients have not been evaluated.

Risankizumab (by subcutaneous injection) for moderate to severe chronic plaque psoriasis

Is Apremilast (Otezla) Effective in Reducing Pruritus in Adults over 18 Years Old with Plaque Psoriasis?

Horizon Scanning Centre May Brodalumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 5524

Etanercept: a new option in paediatric plaque psoriasis

Ustekinumab (Stelara )

Common Psychiatric disorders amongst patients with Psoriasis: A Tertiary Hospital based Case Control Study

Cell-Mediated Immunity and T Lymphocytes

Gender differences in effectiveness of treatment in rheumatic diseases

Psoriatic arthritis FACTSHEET

Paradoxial Safety Signals from Biologics

WHAT CAUSES PSORIASIS TO FLARE UP WHAT CAUSES PSORIASIS TO PDF PSORIASIS PSORIATIC ARTHRITIS MEDLINEPLUS

Cigna Drug and Biologic Coverage Policy

Minami-Hori M, Tsuji H, Takahashi H, Hanada K, Iizuka H

Inflammatory skin disease I Jade Wititsuwannakul, MD Chulalongkorn University, Thailand

The Role of Plasmacytoid Dendritic Cells in Psoriasis

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 13 May 2009

My Algorithm. Questions to ask. Do you or your family have a history of?... Allergic rhinitis, Sensitive skin, Asthma Skin Cancer

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

TRANSPARENCY COMMITTEE OPINION. 26 April 2006

Transcription:

PSORIASIS Dr. Sami Alsuwaidan President, Saudi Society of Dermatology & Dermatologic Surgery Associate Professor and Consultant Department of Dermatology, College of Medicine King Saud University PSORIASIS Is a life long genetically determined autoimmune skin disease characterized by well circumscribed areas of thick, red, scaly skin From the Greek psoros meaning rough, scabby PSORIASIS WHAT S PSORIASIS? FACTS ABOUT PSORIASIS? STIGMATA OF PSORIASIS? MYTHS ABOUT PSORIASIS RECENT NEWS ABOUT PSORIASIS? FACTS ABOUT PROSIASIS Affects 2% of population world wide Affects more than 5% of US population Common disease More understanding and clarity More advances! More confusion! Dynamic!! STIGMATA OF PSORIASIS Typical lesion Typical presentation Affects almost any part of body skin Disfiguring disease Significant pschycologic associations Anatomic sites Scalp (80%) Elbows (78%) Legs (74%) Knees (57%) Nails (10-55%) Gluteal cleft Palms/soles (12%) 1

CLINICAL VARIANTS Chronic plaque psoriasis Guttate psoriasis Erythrodermic psoriasis Generalized pustular psoriasis (von Zumbusch) Localized pustular psoriasis Palmaris et plantaris Acrodermatitis continua Inverse psoriasis PSORIATIC NAIL CHANGES Onycholysis Oil drops Pitting Subungual hyperkeratosis Splinter hemorrhages TRIGGERS FOR PSORIASIS Direct skin injury (Koebner phenomenon) Discontinuation of systemic corticosteroids Streptococcal pharyngitis Emotional stress Alcohol intake Smoking HIV Medications MYTHS ABOUT PSORIASIS It s a contagious disease! It s only a skin disease! Guttate psoriasis is the most common type in children! Guttate psoriasis is a curable disease! Psoriasis can be managed as Eczema Recent news Psoriasis is a systemic disease Arthritis (old) Metabolic syndrome (new) Recent news Psoriasis co-morbidities!!! 2

PSORIASIS IS NOT JUST A SKIN DISEASE Psoriatic arthritis occurs in approximately 30% of patients with psoriasis Depression and alcohol abuse are common in individuals with psoriasis Obesity tends to make psoriasis worse, and psoriasis tends to make obesity worse Severe psoriasis is associated with up to a 7X risk for developing myocardial infarction, especially at a younger age Severe psoriasis is associated with increased mortality (~5 year shorter life span) PSORIASIS AS A SYSTEMIC DISEASE: CHANGING PRACTICE Use systemic therapy more (do TNF- blockers have beneficial effects on metabolic syndrome/cardiovascular risk/mortality?) More monitoring: baseline blood pressure, fasting glucose/lipids More conversations on smoking and alcohol cessation More referrals to internal medicine, nutrition, cardiology, rheumatology, psychiatry, gastric bypass surgery Recent news Therapeutic lines Topical Phototherapy Systemic Biologic therapy BIOLOGIC TREAMENTS FOR PSORIASIS/PSORIATIC ARTHRITIS Etanercept: soluble TNF- receptor Adalimumab: human anti-tnf- mab Infliximab: chimeric anti-tnf- mab Golimumab: human anti-tnf- mab Ustekinumab: human anti-il-12/il-23 mab APPROXIMATE PASI 75 RESPONSES TO BIOLOGICS AT WEEK 12 Etanercept: 40-50% Adalimumab: 60-70% Infliximab: 75-80% Golimumab: 50% Ustekinumab: 70% (80% at week 24) LICHEN PLANUS Lichen Plans LP is an inflammatory skin disease that has characteristic clinical and pathologic features and affects the skin, mucous membranes, nails and hair. 3

Clinical Features of Lichen Planus Typical lesions Wickham s striae Oral involvement Clinical Features of Lichen Planus Nail changes: Thinning/longitudinal ridging Onycholysis/subungual hyperkeratosis Pterygium Clinical Features of Lichen Planus Clinical variants Hypertrophic Annular Lichen planopilaris Ulcerative/Erosive LP 4

Epidemiology Prevalence: 0.3-0.8% world wide 30-60 years Women affected more than men Rare in children Pathogenesis and Etiology Unknown etiology T-cell disease Liver disease association Diagnosis of Lichen Planus Clinical Histopathological Treatment of Lichen Planus Topical corticosteroids Oral corticosteroids Systemic retinoides Hydroxychlorquine Phototherapy Cyclosporine PITYIASIS ROSEA PR is a common acute self limited inflammatory skin disease. Children and young adults are often affected. 5

Clinical Features PATHOLOY PATHOGENESIS AND ETIOLOGY T-Cell Viral MANAGEMENT:? Topical? Systemic 6